Subcutaneous Drug Approved for Cancer Drug

Share on FacebookTweet about this on TwitterShare on LinkedIn

The FDA has approved a supplemental new drug application for a subcutaneous form of bortezomib (Velcade, Millennium). The drug is indicated for the adjuvant treatment of multiple myeloma and mantle cell lymphoma.

Source: Millennium.

Submit a Comment

Your email address will not be published. Required fields are marked *

twenty + 3 =